Feasibility and Safety of a Modified Outpatient Regimen With Intravenous/Intraperitoneal Chemotherapy for Optimally Debulked Stage III Ovarian Cancer

被引:4
|
作者
Bruixola, Gema [1 ]
Domingo, Santiago [2 ]
Diaz, Roberto [1 ]
Caballero, Javier [1 ]
Palomar, Laura [1 ]
De La Cueva, Helena [1 ]
Santaballa, Ana [1 ]
机构
[1] La Fe Univ & Polytech Hosp, Dept Med Oncol, Valencia 46026, Spain
[2] La Fe Univ & Polytech Hosp, Dept Obstet & Gynaecol, Valencia 46026, Spain
关键词
Epithelial ovarian cancer; Chemotherapy; Cisplatin-paclitaxel protocol; Intraperitoneal infusions; Outpatient infusion therapy; INTRAPERITONEAL CHEMOTHERAPY; CISPLATIN; PACLITAXEL; TRIAL; CARBOPLATIN; CARCINOMA;
D O I
10.1097/IGC.0000000000000330
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Intraperitoneal (IP) chemotherapy improves survival in optimally debulked ovarian cancer patients. However, the need for inpatient administration and the perceived higher toxicity rates compared with standard intravenous chemotherapy have limited its widespread application. Several modified outpatient schemes, such as the Spanish Ovarian Cancer Research Group (GEICO) regimen, have been tested and have reported overall better tolerance with an improvement in completion treatment rates. The aim of our study was to assess the toxicity of the GEICO regimen in patients treated at our institution. Methods: We reviewed clinical records of stage III ovarian cancer patients with optimally debulked primary cytoreduction surgery that were treated from June 2009 to April 2013 with the GEICO regimen. Patients received intravenous paclitaxel (175 mg/m(2)) for 3 hours on day 1, IP cisplatin (100 mg/m(2)) on day 2, and IP paclitaxel (60 mg/m(2)) on day 8 every 21 days for a maximum of 6 cycles. Results: Twenty-one patients were identified. In 67% of the patients, IP port placement was performed at the primary surgery. The most common grade 3-to-4 toxicities seen were abdominal pain (14.3%) and neurotoxicity (9.5%). Eighteen patients (85.7%) completed the 6 cycles. Three patients stopped chemotherapy because of treatment-related toxicity. There were no serious port-related complications. With a median follow-up of 46 months, median progression-free survival was 23 months (95% confidence interval [11.8-34.6]). Nine patients (42.9%) have relapsed; most relapses were multifocal and extraperitoneal. Conclusion: The administration of the GEICO outpatient modified regimen was feasible with a good safety profile. It seems to show less toxicity than previously reported IP chemotherapy regimens. In our institution, port-related complications were infrequent and easily managed. However, further studies are warranted to establish the optimal IP regimen in a prospective manner and to validate it in a larger phase 3 trial.
引用
收藏
页码:214 / 221
页数:8
相关论文
共 50 条
  • [41] Peritoneal fibrosis leading to small bowel obstruction two years after first-line intraperitoneal chemotherapy for optimally debulked ovarian cancer
    Chan, Warren S. W.
    Bohmer, Robert
    McIntosh, Robert
    Blomfield, Penelope
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2011, 51 (01): : 91 - 92
  • [42] A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked stage I, II, and III ovarian cancer
    Fyles, AW
    Thomas, GM
    Pintilie, M
    Ackerman, I
    Levin, W
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (03): : 543 - 549
  • [43] Randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked Stage I, II, and III ovarian cancer
    Fyles, Anthony W.
    Thomas, Gillian M.
    Pintilie, Melania
    Ackerman, Ida
    Levin, Wilf
    International Journal of Radiation Oncology, Biology, Physics, 41 (03): : 543 - 549
  • [44] Is platinum-based chemotherapy with paclitaxel effective in optimally debulked patients with advanced ovarian cancer?
    Roovers, JPWR
    Sijmons, EA
    van Leeuwen, JHS
    Mol, BWJ
    Witteveen, PO
    Slee, PHTJ
    Heintz, APM
    EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 97 (01): : 80 - 84
  • [45] DOES NEOADJUVANT CHEMOTHERAPY IMPACT PROGNOSIS IN ADVANCE EPITHELIAL OVARIAN CANCER OPTIMALLY DEBULKED AT SURGERY ?
    Le, T.
    AlMutairi, N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 52 - 52
  • [46] Phase III study of intraperitoneal/intravenous adjuvant chemotherapy compared intravenous adjuvant chemotherapy in patients with stage III gastric cancer.
    Yang, Yang
    Du, Juan
    Wei, Jia
    Guan, Wenxian
    Chen, Gang
    Wang, Meng
    Yu, Lixia
    Qian, Hanqing
    Yang, Yan
    Liu, Baorui
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Conversion of a gastric band into an intraperitoneal port in a patient with optimally debulked stage 3C serous ovarian carcinoma
    Tucker, Paige. E.
    Cohen, Paul. A.
    Tan, Jeremy
    Tan, Jason
    GYNECOLOGIC ONCOLOGY REPORTS, 2015, 12 : 75 - 76
  • [48] Feasibility of intraperitoneal chemotherapy in advanced epithelial ovarian cancer
    Maheshwari, A.
    Gupta, S.
    Prabhash, K.
    Tongaonkar, H. B.
    INDIAN JOURNAL OF CANCER, 2010, 47 (02) : 225 - 226
  • [49] Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
    Tummala, Mohan K.
    Alagarsamy, Suganthi
    McGuire, William P.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1135 - 1147
  • [50] Analysis of progression-free survival, tolerability and toxicity in patients with stage III ovarian, tubal and peritoneal carcinoma treated with an outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin
    Chi, D.
    Dao, F.
    Ferguson, S.
    Sabbatini, P.
    Hensley, M.
    Konner, J.
    Tew, W.
    Bell-McGuinn, K.
    Barakat, R.
    Aghajanian, C.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S123 - S123